In vitro metabolism of ciclesonide, beclomethasone dipropionate, budesonide and fluticasone propionate in human precision-cut lung slicesSource: Eur Respir J 2005; 26: Suppl. 49, 255s Year: 2005
Deposition and metabolism of inhaled ciclesonide in the human lung Source: Eur Respir J 2010; 36: 1113-1119 Year: 2010
High lung deposition of 99m Tc-labelled ciclesonide administered via HFA-MDI to asthma patients Source: Eur Respir J 2004; 24: Suppl. 48, 583s Year: 2004
Relationship between the inhaled and pulmonary absorbed dose of budesonide and mometasone furoate: A study in the isolated perfused rat lung Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
Equivalent pharmacokinetics of the active metabolite of ciclesonide when using the ciclesonide-MDI with and without a spacer Source: Eur Respir J 2004; 24: Suppl. 48, 583s Year: 2004
Airway and systemic effects of hydrofluoroalkane formulations of high dose ciclesonide and fluticasone propionate in moderate persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 583s Year: 2004
Urinary pharmacokinetic method to identify the relative bioavailability of beclometasone dipropionate (BDP) to the lung and body following inhalation Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010
Greater esterification and retention of budesonide in the airways and lung as compared to ciclesonide after repeated intratracheal administration in vivo Source: Eur Respir J 2004; 24: Suppl. 48, 345s Year: 2004
Efficient deposition and absorption of orally inhaled indacaterol in the lungs Source: Annual Congress 2011 - COPD management Year: 2011
Comparison of inhaled ciclesonide, fluticasone propinate and fluticasone propionate + salmeterol in maintaining asthma control Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
Pharmacokinetic bioequivalence of inhaled CHF 1535 50/6 vs. the free combination of beclomethasone and formoterol in asthmatic children Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
The anti-inflammatory effect of budesonide 800 μg/day via Easyhaler® compared with the same dose of budesonide via Turbuhaler® in adult asthmatics Source: Eur Respir J 2001; 18: Suppl. 33, 337s Year: 2001
The absolute bioavailability of fluticasone furoate (FF) and vilanterol (VI) trifenatate following inhaled administration in combination in healthy subjects Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
Effect of inhaled salmeterol or fluticasone on organic dust induced bronchial hyperreactivity Source: Eur Respir J 2002; 20: Suppl. 38, 308s Year: 2002
Budesonide (800 and 1600 μg/day) via Easyhaler® has equivalent systemic activity to the same doses via Turbuhaler® Source: Eur Respir J 2001; 18: Suppl. 33, 100s Year: 2001
Determination of tissue concentrations of metabolites in surgical preparations following inhalation of beclomethasone-dipropionate using conventional and extrafine aerosols Source: Eur Respir J 2003; 22: Suppl. 45, 472s Year: 2003
Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once daily inhalation as a fixed-dose combination in healthy subjects Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019
Variable lipophilicity of budesonide: Comparison with fluticasone propionate, mometasone furoate, and ciclesonide Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003
Efficacy and systemic effects of ciclesonide and fluticasone in asthma patients Source: Eur Respir J 2001; 18: Suppl. 33, 147s Year: 2001
Pharmacokinetics and pharmacodynamics of beclomethasone dipropionate and formoterol combination after inhalation using a new dry powder inhaler Source: Eur Respir J 2007; 30: Suppl. 51, 350s Year: 2007